GeneDx Holdings Corp.
$53.02
+2.0%GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -72.6).
Valuation inputs: P/E -72.6, earnings yield N/A, momentum +2.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -6.8%, ROIC -2.5%).
Profitability stack: net margin -4.9%, ROE -6.8%, ROIC -2.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +46.0%, momentum +2.0%, net margin -4.9%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
GeneDx Holdings Corp. Market vs Earnings Trajectory
Loading price and EPS data...
GeneDx Holdings Corp. Fair Value Envelope
GeneDx Holdings Corp. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
GeneDx Holdings Corp. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
GeneDx Holdings Corp. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
GeneDx Holdings Corp. Street Expectations Map
Wall Street analysts project that WGS stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 96.43, with estimates ranging from a low of 70.00 to a high of 150.00.
The consensus 1-year price target stands at 96.43, with estimates ranging from a low of 70.00 to a high of 150.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
GeneDx Holdings Corp. Insider Positioning
During the last 12 months, insiders have purchased $24.63M and sold $67.04M worth of WGS shares, resulting in $42.41M of net selling activity.
3 Months
519.4K
22.23M
13.1K
951.83K
+21.3M
+$21.28M
3-6 Months
29.2K
2.40M
5.9K
873.15K
+1.5M
+$1.53M
6-9 Months
0
0.00
17.2K
2.19M
-2.2M
-$2.19M
9-12 Months
0
0.00
532.2K
63.03M
-63.0M
-$63.03M
Top Buyers
Casdin Capital, Llc
Director, 10 Percent Owner:
$21.46M
Meister Keith A.
Director, 10 Percent Owner:
$3.17M
Top Sellers
Casdin Capital, Llc
Director, 10 Percent Owner:
$60.45M
Stueland Katherine
Director, Officer: Chief Executive Officer
$4.04M
Feeley Kevin
Officer: Chief Financial Officer
$2.00M
Ruch Joshua
Director
$319K
Ryan Jason
Director
$149K
Insider Activity Analysis
Net Insider Sentiment
Negative insider sentiment with $42.41M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
WGS has not reported any dividend yield values in the available annual periods.
wgs Dividend History
Learning Layer
Related Guides
Build conviction on WGS by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.